JP2013512252A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013512252A5 JP2013512252A5 JP2012541183A JP2012541183A JP2013512252A5 JP 2013512252 A5 JP2013512252 A5 JP 2013512252A5 JP 2012541183 A JP2012541183 A JP 2012541183A JP 2012541183 A JP2012541183 A JP 2012541183A JP 2013512252 A5 JP2013512252 A5 JP 2013512252A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- compound
- salt
- therapeutic agent
- hemi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 46
- 239000003814 drug Substances 0.000 claims 41
- 229940124597 therapeutic agent Drugs 0.000 claims 26
- 150000003839 salts Chemical class 0.000 claims 25
- 239000003795 chemical substances by application Substances 0.000 claims 23
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 239000000945 filler Substances 0.000 claims 15
- 101150053185 P450 gene Proteins 0.000 claims 12
- 229940095064 tartrate Drugs 0.000 claims 12
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims 9
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- 239000007787 solid Substances 0.000 claims 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 9
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 8
- 239000013078 crystal Substances 0.000 claims 8
- 230000036470 plasma concentration Effects 0.000 claims 7
- 238000000634 powder X-ray diffraction Methods 0.000 claims 7
- 239000011230 binding agent Substances 0.000 claims 6
- 239000000314 lubricant Substances 0.000 claims 6
- 230000004060 metabolic process Effects 0.000 claims 6
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 claims 5
- 208000024720 Fabry Disease Diseases 0.000 claims 5
- 208000015872 Gaucher disease Diseases 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 238000012360 testing method Methods 0.000 claims 5
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims 4
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 4
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims 4
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 claims 4
- 229920000881 Modified starch Polymers 0.000 claims 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 229920002472 Starch Polymers 0.000 claims 4
- 229930006000 Sucrose Natural products 0.000 claims 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 4
- 229940049654 glyceryl behenate Drugs 0.000 claims 4
- 229960001021 lactose monohydrate Drugs 0.000 claims 4
- 230000002503 metabolic effect Effects 0.000 claims 4
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims 4
- 239000008107 starch Substances 0.000 claims 4
- 235000019698 starch Nutrition 0.000 claims 4
- 239000005720 sucrose Substances 0.000 claims 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims 3
- 230000001105 regulatory effect Effects 0.000 claims 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical group O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 2
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 2
- 108010010803 Gelatin Proteins 0.000 claims 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 241000209149 Zea Species 0.000 claims 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 2
- 229960004977 anhydrous lactose Drugs 0.000 claims 2
- 239000001506 calcium phosphate Substances 0.000 claims 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 2
- 235000011010 calcium phosphates Nutrition 0.000 claims 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims 2
- 235000013539 calcium stearate Nutrition 0.000 claims 2
- 239000008116 calcium stearate Substances 0.000 claims 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims 2
- -1 copolyvidone Polymers 0.000 claims 2
- 235000005822 corn Nutrition 0.000 claims 2
- 229960002464 fluoxetine Drugs 0.000 claims 2
- 229920000159 gelatin Polymers 0.000 claims 2
- 239000008273 gelatin Substances 0.000 claims 2
- 235000019322 gelatine Nutrition 0.000 claims 2
- 235000011852 gelatine desserts Nutrition 0.000 claims 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 2
- 229960000367 inositol Drugs 0.000 claims 2
- 229960004125 ketoconazole Drugs 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 229960001855 mannitol Drugs 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 229960002296 paroxetine Drugs 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 229960001404 quinidine Drugs 0.000 claims 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 2
- 235000010413 sodium alginate Nutrition 0.000 claims 2
- 239000000661 sodium alginate Substances 0.000 claims 2
- 229940005550 sodium alginate Drugs 0.000 claims 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 229960002668 sodium chloride Drugs 0.000 claims 2
- 239000000600 sorbitol Substances 0.000 claims 2
- 239000006188 syrup Substances 0.000 claims 2
- 235000020357 syrup Nutrition 0.000 claims 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 2
- HOMYIYLRRDTKAA-UHFFFAOYSA-N 2-hydroxy-N-[3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]hexadecanamide Chemical compound CCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=CCCCCCCCCC)COC1OC(CO)C(O)C(O)C1O HOMYIYLRRDTKAA-UHFFFAOYSA-N 0.000 claims 1
- 208000003311 Cytochrome P-450 Enzyme Inhibitors Diseases 0.000 claims 1
- 102000001554 Hemoglobins Human genes 0.000 claims 1
- 108010054147 Hemoglobins Proteins 0.000 claims 1
- 244000043261 Hevea brasiliensis Species 0.000 claims 1
- 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- QPYJXFZUIJOGNX-HSUXUTPPSA-N afegostat Chemical group OC[C@H]1CNC[C@@H](O)[C@@H]1O QPYJXFZUIJOGNX-HSUXUTPPSA-N 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000003205 genotyping method Methods 0.000 claims 1
- 150000002339 glycosphingolipids Chemical class 0.000 claims 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims 1
- 229960002127 imiglucerase Drugs 0.000 claims 1
- 108010039650 imiglucerase Proteins 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- UQRORFVVSGFNRO-UTINFBMNSA-N miglustat Chemical group CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO UQRORFVVSGFNRO-UTINFBMNSA-N 0.000 claims 1
- 229960001512 miglustat Drugs 0.000 claims 1
- 229920003052 natural elastomer Polymers 0.000 claims 1
- 229920001206 natural gum Polymers 0.000 claims 1
- 229920001194 natural rubber Polymers 0.000 claims 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical group C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- FJZZPCZKBUKGGU-AUSIDOKSSA-N CCCCCCCC(N[C@H](CN1CCCC1)[C@@H](c1ccc2OCCOc2c1)O)=O Chemical compound CCCCCCCC(N[C@H](CN1CCCC1)[C@@H](c1ccc2OCCOc2c1)O)=O FJZZPCZKBUKGGU-AUSIDOKSSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26474809P | 2009-11-27 | 2009-11-27 | |
| US61/264,748 | 2009-11-27 | ||
| PCT/US2010/057952 WO2011066352A1 (en) | 2009-11-27 | 2010-11-24 | An amorphous and a crystalline form of genz 112638 hemitartrat as inhibitor of glucosylceramide synthase |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015134942A Division JP6370264B2 (ja) | 2009-11-27 | 2015-07-06 | グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩 |
| JP2016041843A Division JP6452635B2 (ja) | 2009-11-27 | 2016-03-04 | グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013512252A JP2013512252A (ja) | 2013-04-11 |
| JP2013512252A5 true JP2013512252A5 (enExample) | 2014-01-16 |
Family
ID=43431870
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012541183A Pending JP2013512252A (ja) | 2009-11-27 | 2010-11-24 | グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩 |
| JP2015134942A Active JP6370264B2 (ja) | 2009-11-27 | 2015-07-06 | グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩 |
| JP2016041843A Active JP6452635B2 (ja) | 2009-11-27 | 2016-03-04 | グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩 |
| JP2018167432A Active JP7150528B2 (ja) | 2009-11-27 | 2018-09-07 | グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩 |
| JP2020136889A Pending JP2020189873A (ja) | 2009-11-27 | 2020-08-14 | グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩 |
| JP2023101301A Pending JP2023116764A (ja) | 2009-11-27 | 2023-06-21 | グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015134942A Active JP6370264B2 (ja) | 2009-11-27 | 2015-07-06 | グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩 |
| JP2016041843A Active JP6452635B2 (ja) | 2009-11-27 | 2016-03-04 | グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩 |
| JP2018167432A Active JP7150528B2 (ja) | 2009-11-27 | 2018-09-07 | グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩 |
| JP2020136889A Pending JP2020189873A (ja) | 2009-11-27 | 2020-08-14 | グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩 |
| JP2023101301A Pending JP2023116764A (ja) | 2009-11-27 | 2023-06-21 | グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩 |
Country Status (40)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8889127B2 (en) | 2004-07-01 | 2014-11-18 | Icahn School Of Medicine At Mount Sinai | Targeted protein replacement for the treatment of lysosomal storage disorders |
| SG10201407881WA (en) | 2009-11-27 | 2015-01-29 | Genzyme Corp | An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
| WO2012177778A1 (en) * | 2011-06-20 | 2012-12-27 | Mount Sinai School Of Medicine | Anti-tnf- therapy for the mucopolysaccharidoses and other lysosomal disorders |
| EP3741384A1 (en) | 2011-09-07 | 2020-11-25 | Mount Sinai School Of Medicine | Ceramidase and cell differentiation |
| WO2013078413A1 (en) * | 2011-11-22 | 2013-05-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulators of lipid storage |
| CN109529028A (zh) | 2012-06-01 | 2019-03-29 | 西奈山伊坎医学院 | 在感染的治疗和预防中的神经酰胺水平 |
| WO2014160390A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Therapeutic acid ceramidase compositions and methods of making and using them |
| AU2014321397C1 (en) * | 2013-09-20 | 2019-08-01 | Biomarin Pharmaceutical Inc. | Glucosylceramide synthase inhibitors for the treatment of diseases |
| US20170129869A1 (en) * | 2014-07-03 | 2017-05-11 | Dr. Reddy's Laboratories Limited | Amorphous form of eliglustat hemitartarate |
| ES2716420T3 (es) | 2015-04-14 | 2019-06-12 | Sandoz Ag | Clorhidrato de eliglustat cristalino |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| JP6895963B2 (ja) | 2015-11-18 | 2021-06-30 | ジェンザイム・コーポレーション | 多発性嚢胞腎のバイオマーカーおよびその使用 |
| EP3419976B1 (en) | 2016-02-25 | 2021-04-07 | Asceneuron SA | Acid addition salts of piperazine derivatives |
| CN107445938B (zh) * | 2016-05-31 | 2020-04-03 | 北京启慧生物医药有限公司 | 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物 |
| CN106349210A (zh) * | 2016-08-24 | 2017-01-25 | 北京阳光诺和药物研究有限公司 | 一种制备酒石酸艾力骨司坦的方法 |
| EP3318277A1 (en) | 2016-11-04 | 2018-05-09 | Institut du Cerveau et de la Moelle Epiniere-ICM | Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases |
| WO2018193090A2 (en) | 2017-04-21 | 2018-10-25 | Amneal Pharmaceuticals Company Gmbh | Process for preparation of eliglustat hemitartrate and intermediates thereof |
| WO2018225085A1 (en) | 2017-06-05 | 2018-12-13 | Cipla Limited | Stable solid dispersions of eliglustat hemitartrate |
| AU2018283289B2 (en) * | 2017-06-16 | 2021-03-25 | Beta Pharma, Inc. | Pharmaceutical formulations of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof |
| US12472144B2 (en) * | 2017-08-08 | 2025-11-18 | Amneal Pharmaceuticals Llc | Pharmaceutical composition comprising eliglustat |
| WO2019030645A1 (en) | 2017-08-08 | 2019-02-14 | Kashiv Pharma Llc | Pharmaceutical composition comprising eliglustat |
| CN116139130A (zh) * | 2017-12-15 | 2023-05-23 | 建新公司 | 治疗戈谢病的方法 |
| US12064414B2 (en) | 2017-12-20 | 2024-08-20 | Aizant Drug Research Solutions Private Limited. | Stable amorphous Eliglustat premix and process for the preparation thereof |
| WO2019211778A2 (en) * | 2018-05-02 | 2019-11-07 | Kashiv Biosciences, Llc | Pro-drugs of eliglustat |
| WO2019231725A2 (en) * | 2018-05-27 | 2019-12-05 | Bioasis Technolgies Inc. | Treatment of gaucher disease |
| CN110878079A (zh) * | 2018-12-31 | 2020-03-13 | 北京启慧生物医药有限公司 | 一种高纯度依利格鲁司他的制备方法 |
| WO2023280381A1 (en) * | 2021-07-05 | 2023-01-12 | Asceneuron Sa | Medicaments comprising glycosidase inhibitors |
| CN116120274A (zh) | 2021-11-12 | 2023-05-16 | 曙方(上海)医药科技有限公司 | 依利格鲁司他可药用盐及其晶型 |
| WO2026006099A1 (en) | 2024-06-24 | 2026-01-02 | Genzyme Corporation | Eliglustat for the treatment of gaucher disease |
| EP4725474A1 (en) | 2024-10-11 | 2026-04-15 | Genepharm S.A. | A solid composition of eliglustat |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8311286D0 (en) | 1983-04-26 | 1983-06-02 | Searle & Co | Carboxyalkyl peptide derivatives |
| DE3522475A1 (de) | 1985-06-22 | 1987-01-02 | Kali Chemie Pharma Gmbh | Neue aromatische verbindungen, ihre herstellung und verwendung |
| US5041441A (en) | 1988-04-04 | 1991-08-20 | The Regents Of The University Of Michigan | Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol |
| ZA929008B (en) | 1991-12-13 | 1993-05-21 | Bristol Myers Squibb Co | Piperazinyl- and piperidinyl-cyclohexanols. |
| US5302609A (en) | 1992-12-16 | 1994-04-12 | The Regents Of The University Of Michigan | Treatment of diabetic nephropathy |
| US5399567A (en) | 1993-05-13 | 1995-03-21 | Monsanto Company | Method of treating cholera |
| HUT73527A (en) | 1993-08-13 | 1996-08-28 | Seikagaku Kogyo Co Ltd | Remedy for nervous diseases |
| US6309823B1 (en) | 1993-10-26 | 2001-10-30 | Affymetrix, Inc. | Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same |
| EP1008342A3 (en) | 1994-02-02 | 2004-12-29 | The Liposome Company, Inc. | Pharmaceutically active compounds and liposomes, and methods of use thereof |
| WO1995034530A1 (en) | 1994-06-10 | 1995-12-21 | Seikagaku Corporation | 2-acylaminopropanol compound and medicinal composition |
| FR2734819B1 (fr) | 1995-05-31 | 1997-07-04 | Adir | Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant |
| US20030073680A1 (en) | 1995-09-20 | 2003-04-17 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US6255336B1 (en) | 1995-09-20 | 2001-07-03 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| WO2001004108A1 (en) | 1999-07-09 | 2001-01-18 | Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US5916911A (en) | 1995-09-20 | 1999-06-29 | The Regents Of The University Of Michigan | Amino ceramide--like compounds and therapeutic methods of use |
| JP3993908B2 (ja) | 1995-12-08 | 2007-10-17 | 生化学工業株式会社 | アミノアルコール誘導体及び該誘導体の製造方法 |
| NO965193L (no) | 1995-12-08 | 1997-06-09 | Seikagaku Kogyo Kk Seikagaku C | Aminalkoholderivat og fremgangsmåte for fremstilling derav |
| JP4140984B2 (ja) | 1995-12-20 | 2008-08-27 | 生化学工業株式会社 | 分化誘導作用を有する薬剤 |
| US5972928A (en) | 1997-05-21 | 1999-10-26 | Johns Hopkins University | Methods for treatment of conditions associated with lactosylceramide |
| JP4036500B2 (ja) | 1997-05-23 | 2008-01-23 | 生化学工業株式会社 | アミノアルコール誘導体及びそれを含有する医薬 |
| JP4176170B2 (ja) | 1997-06-06 | 2008-11-05 | 生化学工業株式会社 | アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬 |
| US6465488B1 (en) | 1997-12-11 | 2002-10-15 | Chancellor, Masters & Scholars Of The University Of Oxford | Inhibition of glycolipid biosynthesis |
| EP1098642B1 (en) | 1998-07-27 | 2007-04-04 | Johns Hopkins University | Diamino-propanol-compounds for treating ischemia |
| US6610703B1 (en) | 1998-12-10 | 2003-08-26 | G.D. Searle & Co. | Method for treatment of glycolipid storage diseases |
| EP1384719A1 (en) | 1999-07-09 | 2004-01-28 | The Regents of The University of Michigan | Inhibitors of the glucosyl ceramide synthase enzyme useful for the treatment of cancers, sphingolipidosis and microbial infections |
| MXPA02000296A (es) * | 1999-07-09 | 2004-05-21 | Univ Michigan | Compuestos parecidos a aminoceramida y metodos de uso. |
| US20040252299A9 (en) | 2000-01-07 | 2004-12-16 | Lemmo Anthony V. | Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions |
| SK9742002A3 (en) * | 2000-01-07 | 2003-02-04 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| PL358548A1 (en) | 2000-04-24 | 2004-08-09 | Teva Pharmaceutical Industries Ltd. | Zolpidem hemitartrate |
| US6436987B1 (en) | 2000-06-08 | 2002-08-20 | Pfizer Inc. | Crystalline forms of (3S-trans)-2-[3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)-benzoic acid |
| US20020198240A1 (en) | 2001-01-10 | 2002-12-26 | Shayman James A. | Amino ceramide - like compounds and therapeutic methods of use |
| WO2002062777A2 (en) | 2001-01-10 | 2002-08-15 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US20040260099A1 (en) | 2001-01-10 | 2004-12-23 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US7148251B2 (en) | 2001-01-10 | 2006-12-12 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| MXPA03006294A (es) * | 2001-01-18 | 2003-09-16 | Merck Patent Gmbh | Proteinas de fusion disfuncionales con actividad glucocerebrosidasa. |
| PT2266968E (pt) | 2001-07-16 | 2013-02-25 | Genzyme Corp | Síntese de udp-glucose: inibidores de n-acil esfingosinaglucosiltransferase |
| EP1281755A3 (en) | 2001-07-31 | 2003-06-18 | Pfizer Products Inc. | Variants of the human cyp2d6 gene |
| EP1889839B1 (en) | 2001-08-08 | 2013-11-06 | Tobira Therapeutics, Inc. | Bicyclic compound, production and use as HIV inhibitors |
| US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| US20060217560A1 (en) | 2002-04-29 | 2006-09-28 | Shayman James A | Amino ceramide-like compounds and therapeutic methods of use |
| US6916802B2 (en) | 2002-04-29 | 2005-07-12 | Genzyme Corporation | Amino ceramide-like compounds and therapeutic methods of use |
| EP1523310A2 (en) | 2002-07-09 | 2005-04-20 | The Scripps Research Institute | Method to inhibit ischemia and reperfusion injury |
| US20050032070A1 (en) | 2003-08-05 | 2005-02-10 | Sebastian Raimundo | Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications |
| ATE504588T1 (de) * | 2004-01-27 | 2011-04-15 | Synthon Bv | Stabile salze von olanzapin |
| ES2375995T3 (es) | 2004-09-17 | 2012-03-08 | University Of Massachusetts | Composiciones y sus usos para deficiencias de enzima lisosomal. |
| EP1799865B1 (en) | 2004-09-30 | 2012-06-06 | Vanda Pharmaceuticals Inc. | Methods for the administration of iloperidone |
| CA2584246C (en) | 2004-10-13 | 2011-08-09 | Pharmacia & Upjohn Company Llc | Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6h)-yl]-n-(2-hydroxyethyl)-4-methylbenzamide |
| JP2008519840A (ja) * | 2004-11-10 | 2008-06-12 | ジェンザイム・コーポレイション | 糖尿病の処置方法 |
| WO2007038676A2 (en) * | 2005-09-28 | 2007-04-05 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of ladostigil tartrate |
| WO2007040995A1 (en) * | 2005-10-03 | 2007-04-12 | Mallinckrodt Inc. | Process for preparing zolpidem hemitartrate and tartrate polymorphs |
| MX2007016179A (es) | 2006-04-17 | 2008-03-11 | Teva Pharma | Formas cristalinas de o-desmetilvenlafaxina. |
| WO2007134086A2 (en) * | 2006-05-09 | 2007-11-22 | Genzyme Corporation | Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis |
| KR101271225B1 (ko) | 2006-10-31 | 2013-06-03 | 삼성디스플레이 주식회사 | 발광 다이오드 칩 및 발광 다이오드 광원 모듈의 제조 방법 |
| TWI314226B (en) | 2006-12-07 | 2009-09-01 | Ind Tech Res Inst | Piezoelectricity-driving optical lens module |
| EP1961765A1 (en) * | 2006-12-08 | 2008-08-27 | Zealand Pharma A/S | Truncated PTH peptides with a cyclic conformation |
| KR20090104862A (ko) * | 2007-01-12 | 2009-10-06 | 와이어쓰 | 정제내 정제 조성물 |
| MX2009010557A (es) | 2007-03-30 | 2009-11-19 | Amicus Therapeutics Inc | Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas. |
| WO2008134628A2 (en) * | 2007-04-26 | 2008-11-06 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| EP2594562B1 (en) * | 2007-05-31 | 2016-07-20 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
| DE102007029581B4 (de) | 2007-06-26 | 2020-04-09 | GM Global Technology Operations LLC (n. d. Ges. d. Staates Delaware) | Kraftfahrzeugdach und Kraftfahrzeugkarosserie |
| EP2227780A4 (en) | 2008-03-19 | 2011-08-03 | Existence Genetics Llc | GENETIC ANALYSIS |
| WO2009117150A2 (en) * | 2008-03-20 | 2009-09-24 | Genzyme Corporation | Method of treating lupus with ceramide derivatives |
| PL2604608T3 (pl) | 2009-11-27 | 2016-02-29 | Adverio Pharma Gmbh | Sposób wytwarzania {4,6-diamino-2-[1-(2-fluorobenzylo)-1H-pirazolo[3,4-b]pirydyn-3-ylo]pirymidyn-5-ylo}metylokarbaminianu metylu |
| FR2953139B1 (fr) | 2009-11-27 | 2012-04-13 | Servier Lab | Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine |
| NZ599298A (en) | 2009-11-27 | 2014-11-28 | Boehringer Ingelheim Int | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
| SG10201407881WA (en) | 2009-11-27 | 2015-01-29 | Genzyme Corp | An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
| RU2014101626A (ru) | 2011-06-21 | 2015-07-27 | Новартис Аг | Полиморфы 2-амид 1-({4-метил-5-[2-(2, 2, 2-трифтор-1, 1-диметил-этил)-пиридин-4-ил]тиазол-2-ил}амида) (s)-пирролидин-1, 2-дикарбоновой кислоты |
| JO3316B1 (ar) | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
| JP6728842B2 (ja) | 2016-03-24 | 2020-07-22 | オムロン株式会社 | 光学計測装置 |
| CN107445938B (zh) | 2016-05-31 | 2020-04-03 | 北京启慧生物医药有限公司 | 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物 |
| WO2018193090A2 (en) | 2017-04-21 | 2018-10-25 | Amneal Pharmaceuticals Company Gmbh | Process for preparation of eliglustat hemitartrate and intermediates thereof |
-
2010
- 2010-11-24 SG SG10201407881WA patent/SG10201407881WA/en unknown
- 2010-11-24 MX MX2017011301A patent/MX381242B/es unknown
- 2010-11-24 PT PT191827328T patent/PT3599237T/pt unknown
- 2010-11-24 CN CN202010962639.3A patent/CN112521366A/zh active Pending
- 2010-11-24 PE PE2016002590A patent/PE20171255A1/es unknown
- 2010-11-24 MY MYPI2012002297A patent/MY160542A/en unknown
- 2010-11-24 PH PH1/2015/502514A patent/PH12015502514B1/en unknown
- 2010-11-24 ES ES16175117T patent/ES2754398T3/es active Active
- 2010-11-24 ES ES10785289T patent/ES2493940T5/es active Active
- 2010-11-24 ES ES14164650.5T patent/ES2586947T3/es active Active
- 2010-11-24 TW TW099140523A patent/TWI586663B/zh active
- 2010-11-24 KR KR1020227040651A patent/KR20220162824A/ko not_active Ceased
- 2010-11-24 SI SI201031936T patent/SI3133070T1/sl unknown
- 2010-11-24 AR ARP100104348A patent/AR079152A1/es not_active Application Discontinuation
- 2010-11-24 US US13/511,768 patent/US11458119B2/en active Active
- 2010-11-24 HR HRP20140780TT patent/HRP20140780T4/hr unknown
- 2010-11-24 PH PH1/2012/501048A patent/PH12012501048A1/en unknown
- 2010-11-24 JP JP2012541183A patent/JP2013512252A/ja active Pending
- 2010-11-24 SI SI201031252A patent/SI2796457T1/sl unknown
- 2010-11-24 LT LTEP14164650.5T patent/LT2796457T/lt unknown
- 2010-11-24 ME MEP-2016-163A patent/ME02477B/me unknown
- 2010-11-24 HU HUE14164650A patent/HUE029371T2/en unknown
- 2010-11-24 EA EA201592195A patent/EA029990B1/ru not_active IP Right Cessation
- 2010-11-24 PL PL10785289T patent/PL2504332T5/pl unknown
- 2010-11-24 KR KR1020247041119A patent/KR20250005503A/ko active Pending
- 2010-11-24 KR KR1020187012588A patent/KR20180049255A/ko not_active Ceased
- 2010-11-24 LT LT16175117T patent/LT3133070T/lt unknown
- 2010-11-24 TW TW105126084A patent/TWI606827B/zh active
- 2010-11-24 EP EP14164650.5A patent/EP2796457B1/en active Active
- 2010-11-24 SG SG10201800136QA patent/SG10201800136QA/en unknown
- 2010-11-24 RS RS20191404A patent/RS59543B1/sr unknown
- 2010-11-24 CA CA2781676A patent/CA2781676C/en active Active
- 2010-11-24 EP EP16175117.7A patent/EP3133070B1/en not_active Revoked
- 2010-11-24 DK DK16175117T patent/DK3133070T3/da active
- 2010-11-24 PT PT161751177T patent/PT3133070T/pt unknown
- 2010-11-24 NZ NZ715108A patent/NZ715108A/en unknown
- 2010-11-24 CN CN202010962663.7A patent/CN112521367B/zh active Active
- 2010-11-24 WO PCT/US2010/057952 patent/WO2011066352A1/en not_active Ceased
- 2010-11-24 EA EA201890254A patent/EA201890254A3/ru unknown
- 2010-11-24 ES ES19182732T patent/ES2875382T3/es active Active
- 2010-11-24 CN CN201080061535.XA patent/CN102712629B/zh active Active
- 2010-11-24 CA CA3140959A patent/CA3140959A1/en active Pending
- 2010-11-24 PT PT141646505T patent/PT2796457T/pt unknown
- 2010-11-24 PE PE2012000717A patent/PE20121337A1/es not_active Application Discontinuation
- 2010-11-24 PL PL14164650T patent/PL2796457T3/pl unknown
- 2010-11-24 RS RS20160645A patent/RS54978B1/sr unknown
- 2010-11-24 AU AU2010324810A patent/AU2010324810B2/en active Active
- 2010-11-24 NZ NZ625712A patent/NZ625712A/en unknown
- 2010-11-24 PL PL19182732T patent/PL3599237T3/pl unknown
- 2010-11-24 DK DK14164650.5T patent/DK2796457T3/en active
- 2010-11-24 KR KR1020207002751A patent/KR20200013105A/ko not_active Ceased
- 2010-11-24 EP EP10785289.9A patent/EP2504332B2/en active Active
- 2010-11-24 KR KR1020157030851A patent/KR102073207B1/ko active Active
- 2010-11-24 BR BR112012012947A patent/BR112012012947B8/pt active IP Right Grant
- 2010-11-24 EP EP21160074.7A patent/EP3896069A1/en active Pending
- 2010-11-24 IL IL310635A patent/IL310635A/en unknown
- 2010-11-24 MX MX2012006083A patent/MX358345B/es active IP Right Grant
- 2010-11-24 CA CA3075788A patent/CA3075788C/en active Active
- 2010-11-24 SI SI201030715T patent/SI2504332T2/sl unknown
- 2010-11-24 NZ NZ600155A patent/NZ600155A/en unknown
- 2010-11-24 TW TW106124135A patent/TWI656873B/zh active
- 2010-11-24 EP EP19182732.8A patent/EP3599237B1/en active Active
- 2010-11-24 PT PT107852899T patent/PT2504332E/pt unknown
- 2010-11-24 EA EA201270646A patent/EA023923B1/ru not_active IP Right Cessation
- 2010-11-24 PL PL16175117T patent/PL3133070T3/pl unknown
- 2010-11-24 UA UAA201207602A patent/UA113491C2/uk unknown
- 2010-11-24 CN CN201610219151.5A patent/CN105777707B/zh active Active
- 2010-11-24 KR KR1020127016671A patent/KR20120115972A/ko not_active Ceased
- 2010-11-24 DK DK10785289.9T patent/DK2504332T4/da active
- 2010-11-24 RS RS20140446A patent/RS53503B2/sr unknown
- 2010-11-24 CN CN201610218210.7A patent/CN105753846B/zh active Active
- 2010-11-24 HU HUE16175117A patent/HUE045784T2/hu unknown
- 2010-11-24 MY MYPI2019004988A patent/MY192644A/en unknown
-
2012
- 2012-05-18 TN TNP2012000237A patent/TN2012000237A1/en unknown
- 2012-05-20 IL IL219892A patent/IL219892A0/en unknown
- 2012-05-23 DO DO2012000141A patent/DOP2012000141A/es unknown
- 2012-05-24 NI NI201200096A patent/NI201200096A/es unknown
- 2012-05-24 CL CL2012001348A patent/CL2012001348A1/es unknown
- 2012-05-24 EC ECSP12011926 patent/ECSP12011926A/es unknown
- 2012-05-24 CR CR20120277A patent/CR20120277A/es unknown
- 2012-05-25 GT GT201200161A patent/GT201200161A/es unknown
- 2012-06-20 MA MA34989A patent/MA33838B1/fr unknown
-
2014
- 2014-08-28 CY CY20141100690T patent/CY1115880T1/el unknown
-
2015
- 2015-07-06 JP JP2015134942A patent/JP6370264B2/ja active Active
-
2016
- 2016-01-13 US US14/994,489 patent/US20160120842A1/en not_active Abandoned
- 2016-02-22 US US15/049,946 patent/US10888547B2/en active Active
- 2016-03-04 JP JP2016041843A patent/JP6452635B2/ja active Active
- 2016-04-22 AU AU2016202591A patent/AU2016202591B2/en active Active
- 2016-08-11 SM SM201600273T patent/SMT201600273B/it unknown
- 2016-08-17 CY CY20161100807T patent/CY1117996T1/el unknown
- 2016-08-17 HR HRP20161038TT patent/HRP20161038T1/hr unknown
- 2016-09-19 DO DO2016000250A patent/DOP2016000250A/es unknown
- 2016-10-12 CL CL2016002589A patent/CL2016002589A1/es unknown
-
2017
- 2017-11-27 AU AU2017265180A patent/AU2017265180B2/en active Active
-
2018
- 2018-06-27 IL IL260299A patent/IL260299A/en unknown
- 2018-08-23 EC ECSENADI201863798A patent/ECSP18063798A/es unknown
- 2018-09-07 JP JP2018167432A patent/JP7150528B2/ja active Active
-
2019
- 2019-09-12 HR HRP20191647 patent/HRP20191647T1/hr unknown
- 2019-11-13 CY CY20191101196T patent/CY1122698T1/el unknown
-
2020
- 2020-08-14 JP JP2020136889A patent/JP2020189873A/ja active Pending
-
2021
- 2021-01-07 US US17/143,821 patent/US20210369672A1/en not_active Abandoned
- 2021-03-18 AR ARP210100683A patent/AR121612A2/es not_active Application Discontinuation
- 2021-03-18 AR ARP210100682A patent/AR121611A2/es not_active Application Discontinuation
- 2021-06-13 IL IL283935A patent/IL283935A/en unknown
- 2021-09-03 US US17/465,994 patent/US20210393590A1/en not_active Abandoned
-
2022
- 2022-07-14 US US17/865,195 patent/US12465586B2/en active Active
-
2023
- 2023-06-21 JP JP2023101301A patent/JP2023116764A/ja active Pending
-
2025
- 2025-09-26 US US19/342,379 patent/US20260115165A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2670272C2 (ru) | Пероральная фармацевтическая композиция, подходящая для повышения эффективности лечения двигательных нарушений | |
| CN110801452B (zh) | 一种含有阿利沙坦酯水解产物或其水解产物盐的药物组合物及其用途 | |
| AU2010289022B2 (en) | New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine | |
| US20090068290A1 (en) | Bifeprunox doses for treating schizophrenia | |
| TW200803857A (en) | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders | |
| WO2004054574A1 (ja) | 経口固形医薬 | |
| TWI777059B (zh) | 肌肉減少症之預防劑及治療劑 | |
| TWI589292B (zh) | 用於控管噁心及嘔吐之組合物 | |
| WO1998024411A2 (en) | Method for oral administration of buspirone | |
| WO2025038481A1 (en) | Vepdegestrant dosage regimen in cyp3a-inducer treatment in cancer | |
| JPWO2002066030A1 (ja) | ジクロフェナクとオルノプロスチルからなる医薬組成物 | |
| JP7366108B2 (ja) | ロキソプロフェン又はその塩及びビタミンｂ１２類を含有する経口用医薬組成物 | |
| CN101316586A (zh) | 5-ht4激动剂用于治疗可以由质子泵抑制剂诱导的胃排空延迟的用途 | |
| JP2005097277A (ja) | 歯ぎしりの予防剤または治療剤 | |
| JP4355703B2 (ja) | 歯ぎしりの予防剤または治療剤 | |
| JP2018123115A (ja) | 経口固形製剤 | |
| JP2024539116A5 (enExample) | ||
| KR20050016936A (ko) | 당뇨병성 합병증의 예방 또는 진전저지용 의약조성물 | |
| US20260053759A1 (en) | Mesdopetam compositions | |
| JPWO2010024306A1 (ja) | 過敏性腸症候群の治療方法 | |
| TH2101001126A (th) | สารยับยั้ง pde9 สำหรับการบำบัดโรคเม็ดเลือดแดงรูปเคียว | |
| HK1207285B (en) | Orally available pharmaceutical formulation suitable for improved management of movement disorders | |
| TH65242A (th) | รูปแบบยาที่ให้ทางปากสำหรับโพรไพวีรีนหรือเกลือที่สามารถยอมรับได้ทางเภสัชกรรมของมันที่มีการปลดปล่อยส่วนประกอบออกฤทธิ์เร็วที่นานขึ้น | |
| WO2014203140A1 (en) | Solid oral pharmaceutical compositions comprising fixed dose combination of acetaminophen, dicyclomine and dextropropoxyphene or salts thereof |